



In the United States Patent and Trademark Office

PATENT

RECEIVED

RECEIVED

JUL 25 2001

JUL 26 2001

TC 1700

TECH CENTER 1600/290C

In re Application of: Behan, D. et al.

Serial No.: 09/060,188

Filed: April 14, 1998


Art Unit: 1646

Examiner: Basi, N.

**A Method of Identifying Modulators of Cell
Surface Membrane Receptors Useful in the
Treatment of Disease**

Date: July 19, 2001

I HEREBY CERTIFY THAT THIS PAPER IS
BEING DEPOSITED WITH THE UNITED
STATES POSTAL SERVICE "EXPRESS
MAIL" POSTED PREPAID ON THE DATE
INDICATED ABOVE AND IS ADDRESSED
TO THE ASSISTANT COMMISSIONER FOR
PATENTS, WASHINGTON, D.C. 20231.


Ann A. Nguyen
U.S. Reg. No.: 46,087

#25
Y.G.J
7/20/01

Assistant Commission for Patents
Washington, D.C. 20231

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

In accordance with §1.97(b), since this Information Disclosure Statement is being filed within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above-identified application as set forth in §1.491, before the mailing

date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office action after the filing of request for continued examination under §1.114, no additional fee is required.

- In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with the first or second After Final Submission, therefore:
 - Certification in Accordance with §1.97(e) is attached; or
 - The fee of \$180.00 as set forth in §1.17(p) is attached.
- In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or before an action that otherwise closes prosecution in the application, therefore:
 - Certification in Accordance with §1.97(e) is attached; or
 - The fee of \$180.00 as set forth in §1.17(p) is attached
- In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); and the submission fee of \$180.00 as set forth in §1.17(p).
- Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

- In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- In accordance with §1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they are were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. §120 have been made in the instant application:
- Copies of references _____ listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior application Serial No._____, filed on _____.
 - If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1441. This form is submitted in duplicate.

There are no references which are not in the English Language.

Date: July 19, 2001

Ann A. Nguyen
Ann A. Nguyen
Registration No. 46,087

Arena Pharmaceuticals, Inc.
6166 Nancy Ridge Drive
San Diego, CA 92121
Telephone: (858) 453-7200
Facsimile: (858) 677-0065

In the United States Patent and Trademark Office



In re Application of: Behan, D. et al.

Serial No.: 09/060,188

Filed: April 14, 1998


Art Unit: 1646

Examiner: Basi, N.

A Method of Identifying Modulators of Cell Surface Membrane Receptors Useful in the Treatment of Disease

Date: July 11, 2001

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL" POSTED PREPAID ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231.


Ann A. Nguyen
U.S. Reg. No.: 46,087

Assistant Commission for Patents
Washington, D.C. 20231

Dear Sir:

CERTIFICATION UNDER 37 C.F.R. §1.97(e)

In accordance with 37 C.F.R. §1.97(e), certification is hereby made that:

- Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

- No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in connection with a counterpart foreign application, or to the knowledge of the undersigned

after making reasonable inquiry, was known to any individual designated in
§1.56(c) more than three months prior to the filing of the statement.

Date: July 19, 2001

Ann A. Nguyen
Ann A. Nguyen
Registration No. 46,087

Arena Pharmaceuticals, Inc.
6166 Nancy Ridge Drive
San Diego, CA 92121
Telephone: (858) 453-7200
Facsimile: (858) 677-0065